EDN1 and cancer: In that study, Englinger et al., found that a specific signaling pathway, called the ET1/ETA pathway, was overactive in a type of lung cancer cell called DMS114/NIN, and this contributed to the cells’ resistance to a cancer drug called nintedanib.